RBC Capital Reiterates Outperform on Corbus Pharmaceuticals, Maintains $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating for Corbus Pharmaceuticals (NASDAQ:CRBP) and maintained a price target of $82.
August 28, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Corbus Pharmaceuticals and maintained a price target of $82, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a high price target by RBC Capital suggests positive sentiment and confidence in Corbus Pharmaceuticals' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100